Compassion fatigue in pediatric hematology, oncology, and bone marrow transplant healthcare providers: An integrative review

2021 ◽  
pp. 1-11
Author(s):  
Rebecca S. Berger ◽  
Rebecca J. Wright ◽  
Melissa A. Faith ◽  
Stacie Stapleton

Abstract Objective Compassion fatigue (CF), which includes burnout and secondary traumatic stress, is highly prevalent among healthcare providers (HCPs). Ultimately, if left untreated, CF is often associated with absenteeism, decreased work performance, poor job satisfaction, and providers leaving their positions. To identify risk factors for developing CF and interventions to combat it in pediatric hematology, oncology, and bone marrow transplant (PHOB) HCPs. Methods An integrative review was conducted. Controlled vocabulary relevant to neoplasms, CF, pediatrics, and HCPs was used to search PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO, and Web of Science MEDLINE. Inclusion criteria were the following: English language and PHOB population. Exclusion criteria were the following: did not address question, wrong study population, mixed study population where PHOB HCPs were only part of the population, articles about moral distress as this is a similar but not the same topic as CF, conference abstracts, and book chapters. Results A total of 16 articles were reviewed: 3 qualitative, 6 quantitative, 3 mixed methods, and 4 non research. Three themes were explored: (1) high-risk populations for developing CF, (2) sources of stress in PHOB HCPs, and (3) workplace interventions to decrease CF. Significance of results PHOB HCPs are at high risk of developing CF due to high morbidity and mortality in their patient population. Various interventions, including the use of a clinical support nurse, debriefing, support groups, respite rooms, and retreats, have varying degrees of efficacy to decrease CF in this population.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5051-5051
Author(s):  
Abdo S. Haddad ◽  
April Smith ◽  
Brain Bolwell ◽  
Matt Kalaycio

Abstract Response and long term outcome to chemotherapy treatment in patient with AML may differ significantly depending on many factors identified at the time of diagnosis. Age, cytogenetics, and history of myelodysplasia are predictors of survival in patients undergoing induction chemotherapy. AML characterized by t (6;9) (p23; q34) - DEK/CAN fusion occurs only in 1–5% of AML cases. This translocation involves recurrent breakpoints in the DEK gene on chromosome 6p23 andin the CAN gene on chromosome 9q34. It predicts a poor outcome with chemotherapy alone and BMT is usually recommended as a result. However, the curative potential of BMT for t(6; 9) AML patients is unknown. We reviewed our experience treating AML with BMT. Five patients with t (6; 9) AML and one with high-risk myelodysplastic syndrome (MDS) underwent BMT following induction chemotherapy. The prep regimen was Busulfan/Cyclophosphamide in all but one patients and standard GVHD prophylaxis was used. No patient received a T-Cell depleted graft. The median follow up of survivors was 24 months (9–38 months). Our small series provides intriguing data suggesting the potential for cure of patients with AML and t (6; 9). While our data requires confirmation in a larger series of patients, our results provide a rationale to recommend BMT to these high risk patient with AML. Table 1: Characteristics Pt. # Dx Date Age BMT Remission tatus GVHD Relapse A/D Months (Pt. #) Patient number, (Dx) Diagnosis, (BMT) bone marrow transplant date, (GVHD) graft versus host disease, (A/D) Alive/Dead from initial diagnosis, (CR) Complete remission, Matched unrelated donor, and (MSD) Matched sibling donor 1 10/04 37 MSD 6/05 CR1 Yes No A +34 2 06/04 36 MUD 10/06 CR2 NO No A +38 3 03/06 50 MUD 7/06 CR1 NO Yes D +13 4 09/05 20 MUD 12/05 CR1 NO No A +24 5 11/06 39 MSD 2/07 CR1 Yes No A +9 6 10/06 41 MSD 2/07 Refractory No No A +10


Sign in / Sign up

Export Citation Format

Share Document